These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18049941)

  • 21. Vaginal bleeding patterns in women receiving hormone replacement therapy. Impact of various progestogen regimens.
    Thorneycroft IH; Gibbons WE
    J Reprod Med; 1999 Feb; 44(2 Suppl):209-14. PubMed ID: 11392034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
    Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
    BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate.
    Vercellini P; Pietropaolo G; De Giorgi O; Pasin R; Chiodini A; Crosignani PG
    Fertil Steril; 2005 Nov; 84(5):1375-87. PubMed ID: 16275232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in hemostatic parameters after oral and transdermal hormone therapy in postmenopausal women.
    Polac I; Borowiecka M; Wilamowska A; Bijak M; Ponczek MB; Nowak P
    Gynecol Endocrinol; 2011 Sep; 27(9):692-5. PubMed ID: 20979540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does hormone therapy improve age-related skin changes in postmenopausal women? A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women.
    Phillips TJ; Symons J; Menon S;
    J Am Acad Dermatol; 2008 Sep; 59(3):397-404.e3. PubMed ID: 18625536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial.
    de Kraker AT; Kenemans P; Smolders RG; Kroeks MV; van der Mooren MJ
    Eur J Obstet Gynecol Reprod Biol; 2009 Feb; 142(2):139-44. PubMed ID: 19095343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progestin may modify the effect of low-dose hormone therapy on mammographic breast density.
    Panoulis C; Lambrinoudaki I; Vourtsi A; Augoulea A; Kaparos G; Aravantinos L; Christodoulakos G; Creatsas G
    Climacteric; 2009 Jun; 12(3):240-7. PubMed ID: 19387881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction.
    Nijland EA; Nathorst-Böös J; Palacios S; van de Weijer PW; Davis S; Stathopoulos VM; Birkhaeuser MH; von Mauw E; Mulder RJ; Schultz WC;
    Climacteric; 2009 Apr; 12(2):114-21. PubMed ID: 19177255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction of estrogen therapy and thyroid hormone replacement in postmenopausal women.
    Mazer NA
    Thyroid; 2004; 14 Suppl 1():S27-34. PubMed ID: 15142374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.
    Holmberg L; Iversen OE; Rudenstam CM; Hammar M; Kumpulainen E; Jaskiewicz J; Jassem J; Dobaczewska D; Fjosne HE; Peralta O; Arriagada R; Holmqvist M; Maenpaa J;
    J Natl Cancer Inst; 2008 Apr; 100(7):475-82. PubMed ID: 18364505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endometrial safety and bleeding with HRT: what's new?
    Sturdee DW
    Climacteric; 2007 Oct; 10 Suppl 2():66-70. PubMed ID: 17882676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous combined hormone replacement therapy with 1 mg 17beta-oestradiol and 5 mg dydrogesterone (Femoston-conti): endometrial safety and bleeding profile.
    Quereux C; Pornel B; Bergeron C; Ferenczy A
    Maturitas; 2006 Feb; 53(3):299-305. PubMed ID: 16043317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method.
    Eilertsen AL; Karssemeijer N; Skaane P; Qvigstad E; Sandset PM
    BJOG; 2008 May; 115(6):773-9. PubMed ID: 18355366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B-type natriuretic peptide after hormone therapy in postmenopausal women with chest pain and normal coronary angiogram.
    Kawano H; Nagayoshi Y; Soejima H; Tanaka Y; Hokamaki J; Miyamoto S; Miyazaki Y; Yamabe H; Ogawa H
    Menopause; 2008; 15(2):352-6. PubMed ID: 18090872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uterine bleeding with hormone therapies in menopausal women: a systematic review.
    Pickar JH; Archer DF; Goldstein SR; Kagan R; Bernick B; Mirkin S
    Climacteric; 2020 Dec; 23(6):550-558. PubMed ID: 32893694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of estrogen therapy for 1 year on thyroid volume and thyroid nodules in postmenopausal women.
    Ceresini G; Milli B; Morganti S; Maggio M; Bacchi-Modena A; Sgarabotto MP; Chirico C; Di Donato P; Campanati P; Valcavi R; Ceda GP; Braverman LE; Valenti G
    Menopause; 2008; 15(2):326-31. PubMed ID: 17998883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of smoking on bone loss and response to nasal estradiol.
    Bjarnason NH; Nielsen TF; Jørgensen HL; Christiansen C
    Climacteric; 2009 Feb; 12(1):59-65. PubMed ID: 19058059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease.
    Yeboah J; Klein K; Brosnihan B; Reboussin D; Herrington DM
    Menopause; 2008; 15(6):1060-4. PubMed ID: 18521047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An update on the antiestrogenic effect of smoking: a literature review with implications for researchers and practitioners.
    Tankó LB; Christiansen C
    Menopause; 2004; 11(1):104-9. PubMed ID: 14716190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health correlates and mode of administration of hormones--are there any differences between parenteral and oral estrogen preparations?
    Du Y; Schwarz S; Knopf H; Dören M
    Maturitas; 2009 Dec; 64(4):228-34. PubMed ID: 19786334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.